Pharmaceutical Compositions
AssigneeAstraZeneca AB
InventorsHans Eriksson, Martin Brecher, Rohini Chitra, Joan Shaw, Marten Vagero, Ellis Wilson
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treatment with a pharmaceutical composition, more particularly a sustained release pharmaceutical composition, comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, as well as new and improved methods for treating a variety of psychological disorders and conditions including, but not limited to, Mood Disorders and Anxiety Disorders and for treating one or more of the symptoms of these disorders.
Claims76
A method of treating a patient suffering from or susceptible to a Mood Disorder or an Anxiety Disorder comprising administering a sustained release pharmaceutical composition comprising a pharmaceutically effective amount of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine, or a pharmaceutically acceptable salt thereof to the patient in need thereof.
A method of relieving a symptom of depression in a patient comprising administering a therapeutically effective amount of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in a sustained release composition to a patient in need thereof, wherein 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine is administered to the patient once daily, wherein the method excludes administering to the patient other compositions for relieving a symptom of depression.
A method of relieving a symptom of depression in a patient suffering from or susceptible to a Mood Disorder comprising administering a therapeutically effective amount of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in a sustained release composition to a patient in need thereof, wherein 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine is administered to the patient once or twice daily, wherein the 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine is administered as a monotherapy.
A method of relieving a symptom of depression in a patient suffering from or susceptible to Major Depressive Disorder comprising administering a therapeutically effective amount of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in a sustained release composition to a patient in need thereof, wherein 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine is administered to the patient once or twice daily, wherein the 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine is administered as a monotherapy.
A method of treating a patient suffering from or susceptible to an Anxiety Disorder comprising administering to the patient in need thereof a pharmaceutical composition comprising a pharmaceutically effective amount of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine, or a pharmaceutically acceptable salt thereof.
A method of relieving a symptom associated with Generalized Anxiety Disorder in a patient comprising administering a therapeutically effective amount of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in a patient in need thereof, wherein 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine is administered to the patient once daily, wherein the method excludes administering to the patient other compositions for relieving a symptom associated with Generalized Anxiety Disorder.
A method of relieving a symptom associated with Generalized Anxiety Disorder in a patient comprising administering a therapeutically effective amount of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in a patient in need thereof, wherein 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine is administered to the patient once or twice daily, wherein the 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine is administered as a monotherapy.
Use of a sustained release pharmaceutical composition comprising a pharmaceutically effective amount of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a patient suffering from or susceptible to a Mood Disorder or an Anxiety Disorder.
Use of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in a sustained release composition in the manufacture of a once daily medicament for relieving a symptom of depression in a patient.
Use of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in a sustained release composition in the manufacture of a once-daily or twice daily monotherapy medicament for relieving a symptom of depression in a patient suffering from or susceptible to a Mood Disorder.
Use of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in a sustained release composition in the manufacture of a once-daily or twice daily monotherapy medicament for relieving a symptom of depression in a patient suffering from or susceptible to Major Depressive Disorder.
Use of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a patient suffering from or susceptible to an Anxiety Disorder.
Use of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in the manufacture of a once-daily medicament for relieving a symptom associated with Generalized Anxiety Disorder in a patient.
Use of 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine in the manufacture of a once-daily or twice-daily monotherapy medicament for relieving a symptom associated with Generalized Anxiety Disorder in a patient.
Dependencies are inferred from the claim text.